Health Care [ 5/12 ] | Biotechnology [ 18/75 ]
NASDAQ | Common Stock
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
The company has a strategic alliance with SanofiS. A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields.
Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | -0.97 Decreased by -8.99% | -0.79 Decreased by -22.78% |
| Oct 29, 25 | -0.94 Decreased by -14.63% | -0.86 Decreased by -9.14% |
| Aug 11, 25 | -0.95 Decreased by -63.79% | -0.83 Decreased by -14.46% |
| Apr 30, 25 | -0.82 Decreased by -32.26% | -0.73 Decreased by -12.33% |
| Feb 20, 25 | -0.89 Decreased by -256.00% | -0.79 Decreased by -12.92% |
| Oct 31, 24 | -0.82 Increased by +8.89% | -0.84 Increased by +2.38% |
| Aug 7, 24 | -0.58 Increased by +13.43% | -0.68 Increased by +14.71% |
| May 2, 24 | -0.62 Increased by +11.43% | -0.73 Increased by +15.07% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 2.86 M Decreased by -61.32% | -87.03 M Decreased by -23.01% | Decreased by -3.04 K% Decreased by -218.01% |
| Sep 30, 25 | 2.76 M Decreased by -26.12% | -82.17 M Decreased by -31.51% | Decreased by -2.97 K% Decreased by -77.99% |
| Jun 30, 25 | 11.48 M Decreased by -55.26% | -76.61 M Decreased by -82.15% | Decreased by -667.60% Decreased by -307.11% |
| Mar 31, 25 | 22.10 M Increased by +114.83% | -65.58 M Decreased by -35.06% | Decreased by -296.75% Increased by +37.13% |
| Dec 31, 24 | 7.39 M Decreased by -84.56% | -70.75 M Decreased by -392.43% | Decreased by -956.88% Decreased by -3.09 K% |
| Sep 30, 24 | 3.74 M Decreased by -20.88% | -62.49 M Decreased by -18.20% | Decreased by -1.67 K% Decreased by -49.38% |
| Jun 30, 24 | 25.65 M Increased by +55.33% | -42.06 M Decreased by -8.41% | Decreased by -163.98% Increased by +30.21% |
| Mar 31, 24 | 10.29 M Increased by +8.67% | -48.56 M Decreased by -18.64% | Decreased by -472.02% Decreased by -9.17% |